Editorial method
A dose, an indication, a contraindication, or an adverse-reaction percentage must point to the prescribing information or to the trial report that printed it. We name the population in the trial. We do not compare adverse-reaction rates across drugs, because the labels themselves say those rates come from trials run under different conditions.
When two DailyMed records disagree, we use the one whose header shows the later update and we say so. Drugs@FDA application numbers are linked so a reader can see the approval history. Compounding statements cite FDA pages. If this network cannot fetch a page, we still cite the canonical public URL rather than a blog summary, and we do not add details the page did not support when we read it.
The last-reviewed date is the date the sources were checked, which for this first publication is November 18, 2026. The about page explains the empty reviewer field. Corrections are described on the contact page.